Rankings
▼
Calendar
ARCT
Arcturus Therapeutics Holdings Inc.
$217M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$39M
-10.5% YoY
Gross Profit
$39M
100.0% margin
Operating Income
-$11M
-27.7% margin
Net Income
-$7M
-17.8% margin
EPS (Diluted)
$-0.26
QoQ Revenue Growth
-15.6%
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$24M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$371M
Total Liabilities
$109M
Stockholders' Equity
$262M
Cash & Equivalents
$237M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$39M
$43M
-10.5%
Gross Profit
$39M
$43M
-10.5%
Operating Income
-$11M
-$19M
+44.4%
Net Income
-$7M
-$16M
+57.4%
Revenue Segments
Collaboration Revenue
$39M
93%
Grant
$3M
7%
← FY 2024
All Quarters
Q4 2024 →
ARCT Q3 2024 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena